Lipid-core nanocapsules improve the effects of resveratrol against Aβ-induced neuroinflammation

Journal of Biomedical Nanotechnology

Volumn 9, Issue 12, 2013, Pages 2086-2104

  Frozza, Rudimar L ^a   Bernardi, Andressa ^a   Hoppe, Juliana B ^a   Meneghetti, André B ^a   Battastini, Ana M O ^a   Pohlmann, Adriana R ^a   Guterres, Sílvia S ^a   Salbego, Christianne ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Alzheimer's disease; Lipid Core nanocapsules; Neuroinflammation; Neuroprotection; Organotypic culture; Resveratrol

Indexed keywords

ALZHEIMER'S DISEASE; LIPID-CORE NANOCAPSULES; NEUROINFLAMMATION; NEUROPROTECTION; ORGANOTYPIC CULTURE;

CELL DEATH; IMMUNOLOGY; NANOCAPSULES; PATHOLOGY;

RESVERATROL;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; NANOCAPSULE; REACTIVE OXYGEN METABOLITE; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DRUG SYNERGISM; ENCEPHALITIS; HIPPOCAMPUS; INFLAMMATION; LIPIDS; MALE; NANOCAPSULES; NEURONS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; STILBENES;

EID: 84888795902     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1709     Document Type: Article

References (48)

1. E. E. Tuppo and H. R. Arias, The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell. Biol. 37, 289 (2005).
2. E. G. McGeer, P. L. McGeer PL, Neuroinflammation in Alzheimer's disease and mild cognitive impairment: A field in this infancy. J. Alzheimers Dis. 19, 355 (2010).
3. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G. Cole, N. Cooper, P. Eikelenboom, M. Emmerling, B. Fiebich, C. Finch, S. Frautschy, W. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I. Mackenzie, P. McGeer, M. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F. V. Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, and T. Wyss-Coray, Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383 (2000).
4. J. Rogers and L. F. Lue, Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 39, 333 (2001).
5. M. Johnstone, A. J. Gearing, and K. M. Miller, A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced, J. Neuroimmunol. 93, 182 (1999).
6. H. A. Smits, A. Rijsmus, J. H. van Loon, J. W. Wat, J. Verhoef, L. A. Boven, and H. S. Nottet, Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127, 160 (2002).
7. H. Anisman, Cascading effects of stressors and inflammatory immune systemactivation: implications for major depressive disorder. J. Psychiatry Neurosci. 34, 4 (2009).
8. L. J. van Eldik, W. L. Thompson, R. H. Ralay, H. A. Behanna, and W. D. Martin, Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int. Rev. Neurobiol. 82, 277 (2007).
9. J. A. Baur, D. A. Sinclair, Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 5, 493 (2006).
10. M. E. Juan, M. P. Vinardell, and J. M. Planas, The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132, 257 (2002).
11. J. H. Jang and Y. J. Surh, Protective effects of resveratrol on β-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 34, 1100 (2003).
12. Y.-S. Han, W.-H. Zheng, S. Bastianetto, J.-G. Chabot, and R. Quirion, Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmcol. 141, 997 (2004).
13. P. Marambaud, H. Zhao, and P. Davies, Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 280, 37377 (2005).
14. V. Vingtdeux, U. Dreses-Werringloer, H. Zhao, P. Davies, and P. Marambaud, Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 9 (Suppl 2): S6 (2008).
15. S. S. Karuppagounder, J. T. Pinto, H. Xu, H. L. Chen, M. F. Beal, and G. E. Gibson, Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 54, 111 (2009).
16. V. Vingtdeux, L. Giliberto, H. Zhao, P. Chandakkar, Q. Wu, J. E. Simon, E. M. Janle, J. Lobo, M. G. Ferruzzi, P. Davies, and P. Marambaud, AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 285, 9100 (2010).
17. Z. Piñeiro, M. Palma, and C. G. Barroso, Determination of transresveratrol in grapes by pressurised liquid extraction and fast high-performance liquid chromatography. J. Chromatogr. 1110, 61 (2006).
18. A. A. E. Bertelli, L. Giovannini, R. Stradi, S. Urien, J. P. Tillement, and A. Bertelli, Kinetics of trans- and cis-resveratrol (3,4-,5- trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharmacol. Res. 16, 77 (1996).
19. E. Wenzel and V. Somoza, Metabolism and bioavailability of transresveratrol. Mol. Nutr. Food Res. 49, 472 (2005).
20. A. Amri, J. C. Chaumeil, S. Sfar, and C. Charrueau, Administration of resveratrol: What formulation solutions to bioavailability limitations?. J. Control. Release 158, 182 (2012).
21. R. L. Frozza, A. Bernardi, K. Paese, J. B. Hoppe, T. da Silva, A. M. O. Battastini, A. R. Pohlmann, S. S. Guterres, and C. Salbego, Characterization of trans-Resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol. 6, 694 (2010).
22. A. Bernardi, E. Braganhol, E. Jäger, F. Figueiró, M. I. Edelweiss, A. R. Pohlmann, S. S. Guterres, and A. M. O. Battastini, Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 281, 53 (2009a).
23. A. Bernardi, A. C. Zilberstein, E. Jäger, M. M. Campos, F. B. Morrone, J. B. Calixto, A. R. Pohlmann, S. S. Guterres, and A. M. O. Battastini, Effects of indomethacin-loaded nanocapsules in experimental model of inflammation in rats. Br. J. Pharmacol. 158, 1104 (2009b).
24. A. Bernardi, R. L. Frozza, A. P. Horn, M. M. Campos, J. B. Calixto, C. Salbego, A. R. Pohlmann, S. S. Guterres, and A. M. O. Battastini, Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of neuroinflammation. Neurochem. Int. 57, 629 (2010).
25. A. H. Faraji and P. Wipf, Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 17, 2950 (2009).
26. L. Stoppini, P. A. Buchs, and D. Muller, A simple method for organotypic cultures of nervous tissue. J. Neurosc. Method. 37, 173 (1991).
27. R. L. Frozza, A. P. Horn, J. B. Hoppe, F. Simão, D. Gerhardt, R. A. Comiran, and C. G. Salbego, A comparative study of beta-amyloid peptides Aβ1-42 and Aβ25-35 toxicity in organotypic hippocampal slice cultures. Neurochem. Res. 34, 295 (2009).
28. J. B. Hoppe, R. L. Frozza, A. P. Horn, R. A. Comiram, A. Bernardi, M. M. Campos, A. M. O. Battastini, and C. Salbego, Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation. J. Pineal. Res. 48, 230 (2010).
29. E. Jäger, C. G. Venturini, F. S. Poletto, L. M. Colomé, J. P. U. Pohlmann, A. Bernardi, A. M. O. Battastini, S. S. Guterres, and A. R. Pohlmann, Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J. Biomed. Nanotechnol. 5, 130 (2009).
30. S. L. Hempel, G. R. Buettner, Y. Q. O'Malley, D. A. Wessels, and D. M. Flaherty, Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: Comparison with 2′,7′-dichlorodihydrofluorescein diacetate, 5(and 6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. Free Radic. Biol. Med. 27, 146 (1999).
31. R. Liu, W. Liu, S. R. Doctrow, and M. Baudry, Iron toxicity in organotypic cultures of hippocampal slices: role of reactive oxygen species. J. Neurochem. 85, 492 (2003).
32. G. L. Peterson, Review of the folin-phenol protein quantification method of Lowry, Rosebrough, Farr and Randall. Anal. Biochem. 100, 201 (1979).
33. M. Frotscher, S. Zafirov, and B. Heimrich, Development of identified neuronal types and of specific synaptic connection in slice cultures of rat hippocampus. Prog. Neurobiol. 45, 143 (1995).
34. K. Hensley, Neuroinflammation in Alzheimer's Disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers Dis. 21, 1 (2010).
35. C. J. Garwood, A. M. Pooler, J. Atherton, D. P. Hanger, and W. Noble, Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2, 1 (2011).
36. L. L. Zamin, P. Dillenburg-Pilla, R. Argenta-Comiran, A. P. Horn, F. Simão, M. Nassif, D. Gerhardt, R. L. Frozza, and C. Salbego, Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of PI3-K pathway. Neurobiol. Dis. 24, 170 (2006).
37. B. Jannin, M. Menzel, J. P. Berlot, D. Delmas, A. Lancon, and N. Latruffe, Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: Plasmatic protein binding and cell uptake. Biochem. Pharmacol. 68, 1113 (2004).
38. C. Rivière, T. Richard, L. Quentin, S. Krisa, J.-M. Mérillon, and J.-P. Monti, Inhibitory activity of stilbenes on Alzheimer's β-amyloid fibrils in vitro. Bioorg. Med. Chem. 15, 1160 (2007).
39. A. R. A. Ladiwala, J. C. Lin, S. S. Bale, A. M. Marcelino-Cruz, M. Bhattacharya, J. S. Dordick, and P. M. Tessier, Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. J. Biol. Chem. 285, 24228 (2010).
40. J. Shao, X. Li, X. Lu, C. Jiang, Y. Hu, Q. Li, Y. You, and Z. Fu, Enhanced growth inhibition effect of Resveratrol incorporated into biodegradable nanoparticles against glioma cell is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B Biointerfaces 72, 40 (2009).
41. K. Teskac and J. Kristl, The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int. J. Pharm. 390, 61 (2010).
42. M. M. Buchanan, M. Hutchinson, L. R. Watkins, and H. Yin, Toll-like receptor 4 in CNS pathologies. J. Neurochem. 114, 13 (2010).
43. B. Cameron and G. E. Landreth, Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis. 37, 503 (2010).
44. H. Capiralla, V. Vingtdeux, H. Zhao, R. Sankowski, Y. Al-Abed, P. Davies, and P. Marambaud, Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J. Neurochem. 120, 461 (2011).
45. E. Candelario-Jalil, A. C. de Oliveira, S. Graf, H. S. Bhatia, M. Hüll, E. Muñoz, and B. L. Fiebich, Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide- activated primary rat microglia. J. Neuroinflammation 4, 25 (2007).
46. X. Lu, L. Ma, L. Ruan, Y. Kong, H. Mou, Z. Zhang, Z. Wang, J. M. Wang, and Y. Le, Resveratrol differentially modulates inflammatory responses of microglia and and astrocytes. J. Neuroinflammation 7, 46 (2010).
47. S. Mehan, H. Meena, D. Sharma, and R. Sankhla, JNK: A stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J. Mol. Neurosci. 43, 376 (2011).
48. V. Waetzig and T. Herdegen, Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci. Letters 361, 64 (2004).